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Abstract Insulin resistance plays an important role in the
development of type 2 diabetes mellitus (T2DM) and
hypertension. The purpose of the present study was to
evaluate the association between four insulin resistance
genes (ADIPOQ, LEPR, RETN, and TRIB3) and both
T2DM and hypertension. A total of 768 Han Chinese
subjects were recruited into this study, including 188 cases
who had T2DM alone, 223 cases who had hypertension
alone, 181 cases with both T2DM and hypertension, and
176 control subjects with neither T2DM nor hypertension.
Twenty-three tag SNPs in four insulin resistance genes
were genotyped and analyzed for association with T2DM
and hypertension. One intron SNP (rs13306519) in LEPR
and one 30UTR SNP (rs1063537) in ADIPOQ demon-
strated a significant association with T2DM (P = 0.024
and 0.014 respectively). Another intron SNP (rs12037879)
in LEPR and a promoter region SNP (rs266729) in ADI-
POQ were significantly associated with hypertension
(P = 0.041 and 0.042, respectively). These associations
survived the permutation test (P = 0.023, 0.018, 0.026,
and 0.035, respectively). These associations were still
found to be significant in the additive model after adjusting
for potential confounding factors including age, sex, BMI,
HDL, LDL, total cholesterol, and triglyceride levels
(P = 0.024, 0.016, 0.04, and 0.043, respectively). No other
gene variants were found to be significantly associated with
T2DM or hypertension (P [ 0.05). None of the studied
gene variants were found to be significantly associated with
T2DM? hypertension (P [ 0.05). A significant interaction
was observed between two SNPs rs13306519 in LEPR and
rs266729 in ADIPOQ for T2DM (P_int = 0.012, OR_int =
2.67) and hypertension (P_int = 0.0041, OR_int = 2.23).
These findings suggest that variants in ADIPOQ and LEPR
are risk factors for T2DM and hypertension in the Chinese
population and that variants in RETN and TRIB3 are not
major risk factors for these diseases.
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Introduction
Both diabetes and hypertension are important public health
issues throughout the world. To date, at least 285 million
individuals are affected by diabetes (with type II diabetes,
type 2 diabetes mellitus (T2DM), accounting for 80–90 %
of all cases), and that number is expected to reach 438
million by the year 2030 [1]. From 1994 to 2007, the
prevalence of diabetes increased from 2.5 to 9.7 % in
China. This has been attributed the aging of the population,
urbanization, and lifestyle changes [2]. Hypertension
affects nearly 27 % of the population globally and is pre-
dicted to increase by about 60 % to a total of 1.56 billion
people in 2025 [3]. Hypertension affects 18 % of Chinese
adults [4]. High blood pressure is reported in over two-
thirds of patients with T2DM, and its development coin-
cides with the development of hyperglycemia [5].
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Genetic and environmental factors and their interactions
play an important role in the pathogenesis of T2DM and
hypertension [6]. It is assumed that glucose tolerance and
blood pressure are under the control of a large number of
genes, each of which has a relatively mild effect alone. To
date, *40 genetic loci for T2DM and 50 genetic loci for
hypertension have been identified in genome-wide associ-
ation studies [7–9]. Because all these known loci account
for only 10 % of the susceptibility to T2DM and hyper-
tension, candidate gene studies remain a valid and efficient
approach to the identification of new genes and confirma-
tion of the associations between known genes and both
T2DM and hypertension in different populations. The use
of association studies with SNP tags throughout candidate
genes based on their physiological functions is expected to
be a useful strategy for the identification of genes that
contribute to this complex condition.
Reduced glucose tolerance and high blood pressure are
closely associated. Both contribute to cardiovascular mor-
bidity and mortality. Many pathophysiological mechanisms
have been proposed for this association. Of these, insulin
resistance is considered the most plausible and has drawn a
great deal of attention. Genes encoding proteins that can
modulate insulin signaling or action are, by definition,
excellent candidates for the risk modulation of T2DM and
hypertension.
Adipose tissue is considered an endocrine organ. It can
regulate whole-body metabolism and both inflammatory
and immune responses [10]. These actions are mediated by
numerous adipose-tissue-derived hormones, collectively
known as adipokines. These include adiponectin, leptin,
and resistin. The discovery of these endocrine functions of
adipose tissue has prompted the hypothesis that a geneti-
cally influenced dysregulation of the adipokine network
may contribute to the pathogenesis of insulin resistance and
related disorders such as T2DM and hypertension. Adipo-
nectin is a 30 kDa adipocyte-secreted hormone. It is
involved in regulation of blood glucose levels, insulin
sensitivity, and lipid metabolism [11, 12]. The ADIPOQ
gene, which is located on chromosome 3q27, encodes
adiponectin. It has been identified as a susceptibility locus
for T2DM in genome-wide linkage studies and genome-
wide association studies [13–16]. The ADIPOQ gene has
also been implicated in the etiology of hypertension [17].
The leptin receptor (LEPR) is a single-transmembrane-
domain receptor of the cytokine-receptor family. It is dis-
tributed widely in the tissue and it has several alternatively
spliced isoforms [18]. There is growing evidence indicating
that LEPR may play a wide role in human metabolism of
insulin, glucose, and triglycerides. The participation of
leptin in the hypothalamus has been reported to increase
blood pressure through the LEPR [19]. Recent studies have
identified associations between variants in the LEPR gene
and both T2DM and blood pressure [20–24]. Resistin is a
macrophage-derived signaling polypeptide hormone. In
humans it has a molecular weight of 12.5 kDa and a
length of 108 amino acids. Previous animal studies, have
suggested that resistin may play an important role in the
pathogenesis of insulin resistance [25, 26]. The resistin
(RETN) gene, located on 19p12.2, has been associated
with T2DM in several prospective epidemiological
studies across a wide variety of population groups, but
results have been conflicting [27] Studies on biological
function, epidemiology, and genetics, indicate that ADI-
POQ, LEPR, and RETN may be associated with T2DM
and hypertension.
Tribbles homolog 3 (TRIB3) is a 45 kDa pseudokinase,
involved in the impairment of insulin signaling by affecting
insulin-induced Akt activation in several insulin target
tissues [28]. The TRIB3 gene, located on chromosome
20p13, is associated with T2DM [29, 30]. This makes
TRIB3 an excellent candidate for T2DM. In addition,
because insulin resistance is the physiopathologic founda-
tion of more than one metabolic syndrome, TRIB3 gene
may also be associated with high blood pressure.
In the present study, we evaluated the association
between 4 insulin resistance genes (ADIPOQ, LEPR,
RETN, and TRIB3) and both T2DM and hypertension. We
found several SNPs in LEPR and ADIPOQ to be signifi-
cantly associated with T2DM and hypertension.
Methods
Cases and control subjects
The study protocol was approved by the Ethics Committee
for Human Research of Jilin University. Informed consent
was obtained from all participants after explanation of the
nature and possible consequences of the study. In the sur-
vey, verbal consents were recorded but no written consent.
Because the persons are old and most illiterate, well-
trained clerks presented at the discussion with the patient
and made independent record of his or her observations
with impartial witness. Jilin University Ethics Committee
approved this procedure.
A total of 768 Chinese subjects were recruited into this
study, including 188 cases with T2DM alone, 223 cases
with hypertension alone, 181 cases with both T2DM and
hypertension, and 176 control subjects with neither T2DM
nor hypertension (Table 1). The diagnosis of T2DM was
based on clinical and laboratory criteria as defined by the
World Health Organization in 1999. We excluded patients
with MODY and type I diabetes using fasting blood glu-
cose, clinical information, and personal patient histories.
None of the patients with T2DM had ever had ketoacidosis.
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The T2DM treatment included oral anti-diabetic drugs and
insulin. Blood pressure was measured after a 10 min rest at
a sitting position. Hypertension was defined as a mean
systolic blood pressure [140 mmHg and/or a mean dia-
stolic blood pressure [90 mmHg. Patients taking any
antihypertensive medication were defined as hypertensive.
Exclusion criteria included the presence of any of sec-
ondary cause of hypertension, such as chronic renal dis-
ease, renal arterial stenosis, primary aldosteronism,
contraction of the aorta, thyroid disorders, Cushing syn-
drome, and pheochromocytoma. The presence of these
criteria were confirmed through extensive clinical exam-
inations and investigations (including blood chemistry,
renal function tests, endocrine examination, and abdominal
sonogram). Control subjects were collected from the same
geographic regions as the patients with T2DM and hyper-
tension and had similar ethnic backgrounds. They had no
known personal or family history of diabetes or hyperten-
sion. Demographic data including age, sex, weight, height,
duration of diabetes, and hypertension or current use of
anti-hypertensive medications were recorded via inter-
viewer-administered questionnaires. All subjects were Han
Chinese from northeastern China.
Polymorphisms and genotyping
Venous blood samples were collected in EDTA-containing
tubes from all participants after an overnight fast of at least
10 h. Genomic DNA was extracted from peripheral blood
leukocytes. Tag SNPs were selected to cover the whole
gene regions of ADIPOQ, LEPR, RETN, and TRIB3
according to the HapMap Han Chinese population (Phase
II ? III, release 27; Table 2). The tag SNPs located in
exons and promoter regions were selected in higher pri-
ority. The selected tag SNPs captured all SNPs from 5 kb
upstream to 5 kb downstream of the respective genes with
r2 [ 0.8 and minor allele frequency (MAF) [0.1. SNP
genotyping was performed by Bio Miao Biological
Technology Co. Ltd. (Beijing, China) using a MassAR-
RAY system (Sequenom, San Diego, CA, USA) with the
iPLEX assay.
Statistical analysis
Demographic and clinical characteristics were compared
between cases and control subjects by using either the chi
square test for categorical data or unpaired t test for
numerical data as appropriate. Data analyses for SNPs were
performed using PLINK (v1.07) [31]. Hardy–Weinberg
equilibrium was assessed by using the chi square test.
Minor allele frequencies of each SNP between cases and
control subjects were compared using Fisher’s exact test.
The odds ratio (OR) and 95 % confidence interval (CI)
were calculated using logistic regression. A permutation
test was performed using the label-swapping and
max(T) procedures for 10,000 permutations. The associa-
tions between the SNPs and the diseases were further
evaluated using logistic regression after adjusting for
potential confounding factors including age, sex, BMI,
HDL, LDL, total cholesterol, and triglyceride levels. An
additive effects model was applied to analysis of allele
dosage in which the genotypes AA, AB, BB were coded as
0, 1, and 2, respectively. A represents the rare allele and B
represents the common allele. Pairwise SNP–SNP inter-
actions were analyzed using logistic regression. Multiple
comparisons were corrected using the Bonferroni method.
Results
Demographic and clinical characteristics of the study
subjects are summarized in Table 1. There was a signifi-
cant difference in gender (P = 0.01) and age (P = 0.02)
between cases with hypertension and control subjects.
All SNPs were found to be in Hardy–Weinberg equi-
librium in the control group (P [ 0.01). One intron SNP
Table 1 Demographic and
clinical features of the study
subjects
DM represents type 2 diabetes,
HT represents hypertension
* P \ 0.05 versus controls
Group DM HT DM ? HT Control subjects
Number of subjects 188 223 179 176
Gender (M/F) 62/126 67/156* 59/120 75/101
Age at examination (years) 67.9 ± 6.7 68.8 ± 6.7* 68.2 ± 6.1 67.1 ± 7.1
Body mass index (kg/m2) 24.1 ± 4.0* 24.5 ± 4.3* 26.0 ± 3.7* 23.1 ± 3.3
Systolic blood pressure (mmHg) 128.1 ± 17.3* 154.6 ± 21.0* 153.1 ± 19.9* 121.3 ± 10.9
Diastolic blood pressure (mmHg) 78.6 ± 9.8 90.2 ± 10.1* 88.5 ± 12.4* 76.8 ± 7.8
Glucose (mmol/l) 7.4 ± 2.0* 5.3 ± 0.5 7.1 ± 1.7* 5.3 ± 0.5
HDL (mmol/l) 1.4 ± 0.4 1.4 ± 0.4 1.5 ± 0.5* 1.4 ± 0.4
LDL (mmol/l) 3.3 ± 0.9 3.3 ± 0.9 3.3 ± 0.9 3.2 ± 0.8
Total cholesterol (mmol/l) 5.2 ± 1.1 5.2 ± 1.2 5.3 ± 1.2 5.1 ± 0.9
Triglycerides (mmol/l) 1.9 ± 1.0* 1.7 ± 0.8 1.9 ± 0.9* 1.6 ± 0.99
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(rs13306519) in LEPR and one 30UTR SNP (rs1063537) in
ADIPOQ demonstrated a significant association with
T2DM (P = 0.024 and 0.014 respectively; Table 3). The
allele G frequency of rs13306519 was higher in cases with
T2DM than in the control subjects (20.6 vs. 13.8 %;
OR = 1.62; 95 % CI, 1.07–2.45). The allele T frequency
of rs1063537 was lower in cases with T2DM than in the
control subjects (26.8 vs. 36.3 %; OR = 0.64; 95 % CI,
0.45–0.91). Another intron SNP (rs12037879) in LEPR and
a promoter region SNP (rs266729) in ADIPOQ were sig-
nificantly associated with hypertension (P = 0.041 and
0.042 respectively; Table 3). The allele A frequency of
rs12037879 was higher in cases with hypertension than in
the control subjects (22.8 vs. 16.2 %; OR = 1.53; 95 % CI,
1.03–2.26). The allele G frequency of rs266729 was higher
in cases with hypertension than in the control subjects (34.3
vs. 27.0 %; OR = 1.41; 95 % CI, 1.02–1.95). These
associations survived the permutation test (P = 0.023,
0.018, 0.026, and 0.035, respectively). These associations
remained significant in the additive model after adjusting
for potential confounding factors including age, sex, BMI,
HDL, LDL, total cholesterol, and triglyceride levels
(P = 0.024, 0.016, 0.04, and 0.043, respectively). No other
gene variants were found to be significantly associated with
T2DM and hypertension (P [ 0.05). None of the gene
variants studied here was found to be significantly associ-
ated with T2DM? hypertension (P [ 0.05).
SNP–SNP interaction analysis identified a signifi-
cant interaction between two SNPs rs13306519 in LEPR
and rs266729 in ADIPOQ for T2DM (P_int = 0.012,
OR_int = 2.67) and hypertension (P_int = 0.0041,
OR_int = 2.23).
Discussion
In present study, we evaluated 23 tag SNPs in 4 critical
insulin resistance genes for association with T2DM and
hypertension in the Chinese Han population. We found one
SNP in ADIPOQ, rs1063537, and one SNP in LEPR,
rs13306519, to be significantly associated with T2DM. An
SNP in ADIPOQ, rs266729, and another SNP in LEPR,
Table 2 Characteristics and genotype counts of the 26 variants in 4 insulin resistance genes
Gene SNP Chr Position (bp)a Location Alleles (A/B)b Genotype Count (AA/AB/BB)b
DM HT DM ? HT Control subjects
LEPR rs12037879 1 65,942,707 Intron 1 A/G 8/55/106 8/68/108 6/57/97 2/45/104
LEPR rs7554485 1 65,945,906 Intron 1 C/T 1/21/118 4/22/111 0/23/105 1/22/88
LEPR rs1137100 1 66,036,441 Exon 2 A/G 1/40/96 2/35/98 2/41/88 3/35/72
LEPR rs13306519 1 66,037,929 Intron 3 G/C 7/58/110 6/62/126 7/50/110 4/35/117
LEPR rs1137101 1 66,058,513 Exon 4 A/G 3/34/140 5/42/146 1/31/133 3/33/117
LEPR rs8179183 1 66,075,952 Exon 9 C/G 0/15/117 1/14/114 0/19/109 0/9/96
ADIPOQ rs16861194 3 186,559,425 50NEAR G/A 9/43/127 5/55/138 4/47/118 7/46/109
ADIPOQ rs266729 3 186,559,474 50NEAR G/C 11/69/96 23/90/85 12/68/93 11/64/84
ADIPOQ rs12495941 3 186,568,180 Intron 1 T/G 35/78/63 24/101/74 25/88/56 20/80/57
ADIPOQ rs2241766 3 186,570,892 Exon 1 G/T 14/75/91 14/86/102 12/67/90 10/65/91
ADIPOQ rs1501299 3 186,571,123 Intron 2 A/C 13/69/88 18/58/109 12/65/84 7/68/74
ADIPOQ rs1063537 3 186,574,075 30UTR T/C 11/59/81 45/79/70 18/57/75 25/56/65
ADIPOQ rs12629945 3 186,577,127 30NEAR A/G 9/49/98 9/56/99 5/42/98 6/46/81
ADIPOQ rs6444175 3 186,579,744 3 NEAR A/G 15/72/95 19/65/113 12/70/88 6/78/78
RETN rs2161490 19 7,731,954 5 NEAR T/C 28/85/68 36/102/64 34/83/55 31/78/56
RETN rs3745368 19 7,735,297 3 UTR A/G 6/43/131 4/52/144 3/44/125 4/35/122
TRIB3 rs12626158 20 370,150 Intron 2 A/G 9/61/108 23/56/127 12/59/97 9/48/98
TRIB3 rs6051637 20 371,972 Exon 2 T/C 7/66/103 4/60/130 6/50/112 7/46/105
TRIB3 rs6115830 20 377,226 Exon 3 T/C 16/77/87 23/85/94 14/72/85 20/72/70
TRIB3 rs2295491 20 377,979 30UTR A/G 0/37/135 5/47/137 0/43/122 5/36/112
TRIB3 rs2295492 20 378,242 3 NEAR C/G 6/46/120 7/54/130 5/39/121 4/49/100
TRIB3 rs6037542 20 382,876 3 NEAR T/G 11/78/86 19/93/77 17/73/77 13/76/65
DM represents type 2 diabetes, HT represents hypertension
a Chromosomal position is based on NCBI Build 37.3 (National Center for Biotechnology Information, Bethesda, MD, USA)
b A represents the minor allele and B represents the common allele
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rs12037879, were significantly associated with hyperten-
sion. These findings suggest that ADIPOQ and LEPR,
which encode proteins associated with insulin resistance,
may play an important role in the development of T2DM
and hypertension.
ADIPOQ is considered a gene for T2DM and metabolic
syndrome. The concentration of adiponectin in the plasma
has been suggested to play an important role in the mod-
ulation of insulin sensitivity and glucose homeostasis. It
has also been found to be decreased in patients with T2DM,
hypertension, dyslipidemia, coronary artery disease, and
obesity [32–37]. All of these conditions are closely related
to insulin resistance. In line with plasma levels of adipo-
nection, the ADIPOQ gene has been identified as a sus-
ceptibility locus for the metabolic syndrome, T2DM, and
cardiovascular disease. However, studies of the associa-
tions between the ADIPOQ gene with adiponectin level
and the metabolic syndrome often show conflicting results
[38, 39]. Studies on the associations between ADIPOQ
SNPs with T2DM and hypertension in Chinese populations
have also produced conflicting results [17, 40–42]. SNP
rs2241766 in exon 2 and SNP rs1501299 in intron 2 are the
most widely investigated variants in ADIPOQ. At least 19
studies have shown SNP rs2241766 to be associated with
T2DM in the Chinese population, but no association was
found in any of 8 other studies [40]. A recent large-scale
meta-analysis of 39 studies showed that SNPs rs2241766
and rs1501299 are not associated with T2DM in either
Asian or European populations [42]. A meta-analysis of 24
studies suggested no significant association between SNPs
rs2241766 and rs1501299 and hypertension in Chinese
individuals [41]. A large cardiovascular risk factor preva-
lence study also failed to find any association between
SNPs rs2241766 and rs1501299 and hypertension [17]. In
the present study, we did not find any significant associa-
tion between these 2 SNPs and either T2DM or hyperten-
sion, which is consistent with previous studies [41, 42].
Intriguingly, three polymorphisms (rs16861194, rs17300539,
rs266729) in ADIPOQ were associated with risk of T2DM
in European populations but none of these polymorphisms
were associated with risk of T2DM in Asian populations
[42]. In the present study, no significant association was
Table 3 Single-SNP association of the studied genes with T2DM, hypertension, and both
Gene SNP Minor allele MAF P*
DM HT DM ? HT Control subjects DM HT DM ? HT
LEPR rs12037879 A 0.210 0.228 0.216 0.162 0.13 0.041 0.10
LEPR rs7554485 C 0.082 0.110 0.090 0.108 0.36 1.00 0.54
LEPR rs1137100 A 0.153 0.144 0.172 0.186 0.34 0.22 0.72
LEPR rs13306519 G 0.206 0.191 0.192 0.138 0.024 0.07 0.07
LEPR rs1137101 A 0.133 0.135 0.100 0.128 0.63 0.82 0.32
LEPR rs8179183 C 0.057 0.062 0.074 0.043 0.53 0.41 0.17
ADIPOQ rs16861194 G 0.170 0.164 0.163 0.185 0.62 0.49 0.47
ADIPOQ rs266729 G 0.259 0.343 0.266 0.27 0.73 0.042 0.93
ADIPOQ rs12495941 T 0.421 0.374 0.408 0.382 0.34 0.88 0.52
ADIPOQ rs2241766 G 0.286 0.282 0.269 0.256 0.39 0.45 0.73
ADIPOQ rs1501299 A 0.279 0.254 0.276 0.275 0.93 0.54 1.00
ADIPOQ rs1063537 T 0.268 0.436 0.310 0.363 0.014 0.06 0.19
ADIPOQ rs12629945 A 0.215 0.226 0.179 0.218 1.00 0.84 0.29
ADIPOQ rs6444175 A 0.280 0.261 0.277 0.278 1.00 0.67 1.00
RETN rs2161490 T 0.390 0.431 0.439 0.424 0.35 0.88 0.76
RETN rs3745368 A 0.153 0.150 0.145 0.134 0.51 0.59 0.74
TRIB3 rs12626158 A 0.222 0.248 0.247 0.213 0.85 0.29 0.35
TRIB3 rs6051637 T 0.227 0.175 0.185 0.19 0.25 0.62 0.92
TRIB3 rs6115830 T 0.303 0.324 0.292 0.346 0.25 0.58 0.16
TRIB3 rs2295491 A 0.108 0.151 0.130 0.15 0.13 1.00 0.49
TRIB3 rs2295492 C 0.169 0.178 0.149 0.186 0.61 0.84 0.20
TRIB3 rs6037542 T 0.286 0.347 0.320 0.331 0.24 0.69 0.80
Significant SNPs and P values are shown in bold type
DM represents type 2 diabetes, HT represents hypertension
* Obtained from Fisher’s exact test versus control subjects
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observed between SNPs rs16861194 and rs266729 with
T2DM in a Chinese Han population. Taken together, these
findings suggest that ethnically specific polymorphisms
might contribute to the development of T2DM and
hypertension in different populations.
In the present study, we found the G allele of a promoter
SNP rs266729 in ADIPOQ to be significantly associated
with the increased risk of hypertension (OR = 1.41). A
previous study in a Hong Kong Chinese population also
suggested that genetic variants in the promoter region of
ADIPOQ are associated with increased risk of hypertension
[17]. The G allele of rs266729 has been linked to decreased
serum levels of adiponectin [43]. Because adiponectin has
been reported to exert an antiatherosclerotic effect, we
might speculate that G allele of rs266729 can influence the
abundance expressor function of adiponectin. Low levels
of this peptide in serum can directly influence endothelial
function. This hypothesis is supported by the observation
that both the expression and activity of eNOS are increased
in cultured vascular endothelial cells that have been treated
with globular adiponectin [44]. This promoter polymor-
phism is also associated with T2DM in Chinese, French,
German, and Swedish populations [22, 40, 45, 46]. One
meta-analysis confirmed the association between rs266729
and T2DM, but another meta-analysis did not [39, 47]. The
discrepancy between these results may be partially due to
ethnic differences in the populations, selection criteria of
the study subjects, and sample size.
It has been proposed that SNPs in the 30UTR of ADI-
POQ, like promoter SNPs, may remodel adiponectin con-
formation, causing T2DM [48]. In the present study, one
30UTR SNP, rs1063537, found in ADIPOQ, was found to
be significantly associated with T2DM. To the best of our
knowledge, this is the first time that this SNP has been
shown to be associated with T2DM. One previous study
reported the T allele of rs1063537 to be associated with
higher adiponectin levels in Caucasian women [49]. Other
research groups found another 2 SNPs (rs1063539 and
rs6773957) in 30UTR of ADIPOQ to be associated with
T2DM in the Chinese population [50, 51]. SNP rs6773957
was found to be associated with adiponectin level in a
genome-wide association study [52]. The HapMap data in
Asian samples show that rs1063537 is in linkage disequi-
librium with rs1063539 and rs6773957.
Genetic variants in the LEPR gene have been reported to
have a profound impact on body weight, insulin resistance,
blood pressure, and other metabolic disease parameters
[23, 38]. In the present study, we found one intron SNP,
rs13306519, in LEPR to be significantly associated with
T2DM and another intron SNP rs12037879 was found to be
significantly associated with hypertension. To our knowl-
edge, this is the first time that these two LEPR SNPs have
been associated with T2DM and hypertension. Further
studies in different populations are needed to confirm our
findings.
The nonsynonymous SNP rs1137101 (Gln223Arg),
which is in the LEPR gene, has been extensively investi-
gated in a wide range of populations. The G allele of
rs1137101 has been associated with lower blood pressure
[23]. However, the A allele has been associated with
increased insulin and leptin levels and the risk of devel-
oping T2DM [53]. Another two nonsynonymous SNPs,
rs8179183 (Lys656Asn) and rs1137100 (Arg109Lys), have
been reported to be associated with hypertension and
T2DM [54, 55]. However, the results of published studies
have been inconsistent [23, 53]. One study performed in
the Chinese population showed rs1137101 to be associated
with hypertension but not with T2DM [56]. In the present
study, we did not find any association between these 3
SNPs with T2DM or hypertension. This could be partly
explained by a lack of statistical power sufficient to detect
variants that are likely to confer only a modest effect on
T2DM and hypertension. Further studies with larger sam-
ple size and greater statistical power are required to con-
firm these associations.
Intriguingly, a significant interaction was identified
between two SNPs rs13306519 in LEPR and rs266729 in
ADIPOQ for both T2DM (P_int = 0.012, OR_int = 2.67)
and hypertension (P_int = 0.0041, OR_int = 2.23), sug-
gesting that individuals carrying variants of both genes
might have a higher risk of developing T2DM and hyper-
tension than those carrying variants in single genes.
The RETN and TRIB3 genes have been found to be
associated with T2DM in previous studies, but the results
are often conflicting [27, 29, 30]. In the present study, no
significant association was found between the RETN and
TRIB3 genes and any medical condition, suggesting that
genetic variants in these genes may not be major risk
factors for the development of T2DM or hypertension in
the Chinese population.
It is crucial to avoid population stratification in genetic
association studies. One of the strengths of the present
study is the ethnically matched cases and control subjects.
The observed association in our study is unlikely to have
been affected by population stratification. Another major
strength of our study is the relatively large sample size in
both the disease and control groups. Although the sample
size examined in the present work is smaller than those of
other large-scale studies, the power calculations suggest
that these samples have sufficient power to detect common
variants with moderate genetic effects. Specifically, these
samples for T2DM had 86.7 % power to detect variants
with minor allele frequencies of 0.15 and OR of 1.6 at
significance level of 0.05. The samples for hypertension
had 91.7 % power to detect variants with minor allele
frequencies of 0.15 and ORs of 1.6 at a significance level of
930 Mol Biol Rep (2014) 41:925–933
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0.05. All four genes investigated in this study have been
found to be associated with T2DM and hypertension in
previous studies, but the results are often conflicting. The
purpose of the present study was to evaluate these associ-
ations in a different population. Because this study was not
a discovery study, we did not attempt to replicate our
results in independent samples. One limitation of the
present study was that we did not investigate rare variants
but only SNP tags with a MAF [0.1. We therefore could
not rule out the possibility of the existence of rare variants
in these genes that might be associated with T2DM and
hypertension. Our sample size would not provide sufficient
power for a detection of the associations of these rare
variants with T2DM and hypertension. A larger sample and
resequencing of the whole gene coding regions would be
required to elucidate the role of these rare variants in the
development of T2DM and hypertension. Although the
selected tag SNPs evaluated in this study are not sufficient
to define fine structure of the haplotype block in this
population, the purpose of the present study was to inves-
tigate the association of these genes with T2DM and
hypertension. It was anticipated that these selected tag
SNPs would be capable of capturing the majority of
polymorphisms in these genes. As the associations we
observed in the present study were nominally significant, it
is possible that these associations are false positives.
However, it is statistically impossible for a candidate gene
study like this one to yield a very small P values like those
reported in a genome-wide association studyies with
thousands of samples. Permutation tests suggest that these
nominal associations are likely to be true associations.
Serum levels of adipokines, including adiponectin, lep-
tin, and resistin, have been reported to be involved in the
development and progression of both T2DM and hyper-
tension. Genetic variants in genes encoding these adipo-
kines have been found to be associated with serum levels of
these adipokines. It would be interesting to investigate the
association between the gene variants and the serum levels
of these adipokines. However, because serum levels of
these adipokines were not measured in the present study, it
is impossible to perform such an analysis as part of this
project. Further studies are warranted.
In summary, the present findings suggest that variants in
ADIPOQ and LEPR are significant risk factors for T2DM
and hypertension. However, variants in RETN and TRIB3
are not major risk factors for the development of these
complex disorders, at least in the Chinese population.
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